NASDAQ:PRNB - Principia Biopharma Stock Price, News, & Analysis

$38.58
-1.52 (-3.79 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
$38.21
Now: $38.58
$41.38
50-Day Range
$29.26
MA: $35.24
$41.45
52-Week Range
$22.00
Now: $38.58
$42.16
Volume40,674 shs
Average Volume181,511 shs
Market Capitalization$920.90 million
P/E Ratio67.68
Dividend YieldN/A
BetaN/A
Principia Biopharma Inc, a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRNB
CUSIPN/A
CIKN/A
Phone650-416-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$69.14 million
Cash Flow$0.1928 per share
Book Value$7.12 per share

Profitability

Miscellaneous

Employees65
Market Cap$920.90 million
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable

Receive PRNB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRNB and its competitors with MarketBeat's FREE daily newsletter.

Principia Biopharma (NASDAQ:PRNB) Frequently Asked Questions

What is Principia Biopharma's stock symbol?

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc (NASDAQ:PRNB) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.62) by $0.05. The business had revenue of $5.16 million for the quarter, compared to analysts' expectations of $8 million. View Principia Biopharma's Earnings History.

When is Principia Biopharma's next earnings date?

Principia Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Principia Biopharma.

What price target have analysts set for PRNB?

6 brokers have issued 1 year price targets for Principia Biopharma's shares. Their predictions range from $42.00 to $55.00. On average, they expect Principia Biopharma's stock price to reach $47.3333 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price. View Analyst Price Targets for Principia Biopharma.

What is the consensus analysts' recommendation for Principia Biopharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Principia Biopharma.

Has Principia Biopharma been receiving favorable news coverage?

News articles about PRNB stock have been trending neutral recently, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Principia Biopharma earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Principia Biopharma.

Are investors shorting Principia Biopharma?

Principia Biopharma saw a increase in short interest in the month of June. As of June 30th, there was short interest totalling 853,200 shares, an increase of 20.5% from the May 30th total of 707,900 shares. Based on an average trading volume of 136,300 shares, the short-interest ratio is currently 6.3 days. Approximately 6.7% of the shares of the company are short sold. View Principia Biopharma's Current Options Chain.

Who are some of Principia Biopharma's key competitors?

What other stocks do shareholders of Principia Biopharma own?

Who are Principia Biopharma's key executives?

Principia Biopharma's management team includes the folowing people:
  • Dr. Alan B. Colowick Ph.D., M.D., M.P.H., Exec. Chairman (Age 57)
  • Mr. Martin Babler, CEO & Director (Age 54)
  • Mr. Christopher Y. Chai, Chief Financial Officer (Age 52)
  • Ms. Stefani A. Wolff, Chief Devel. Officer (Age 57)
  • Dr. David M. Goldstein, Chief Scientific Officer (Age 53)

When did Principia Biopharma IPO?

(PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

How do I buy shares of Principia Biopharma?

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Principia Biopharma's stock price today?

One share of PRNB stock can currently be purchased for approximately $38.58.

How big of a company is Principia Biopharma?

Principia Biopharma has a market capitalization of $920.90 million and generates $69.14 million in revenue each year. The company earns $18.17 million in net income (profit) each year or $0.57 on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.View Additional Information About Principia Biopharma.

What is Principia Biopharma's official website?

The official website for Principia Biopharma is http://www.principiabio.com/.

How can I contact Principia Biopharma?

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]


MarketBeat Community Rating for Principia Biopharma (NASDAQ PRNB)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  63
MarketBeat's community ratings are surveys of what our community members think about Principia Biopharma and other stocks. Vote "Outperform" if you believe PRNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel